Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nine Continents Medical developed a miniaturized implantable tibial nerve stimulator for the treatment of overactive bladder. The device requires no patient activation or recharging and can be implanted via a minimally invasive procedure. Clinical feasibility studies were completed pre-acquisition; pivotal trials were planned for initiation in 2021 to support regulatory submissions in the US and EU[1][3].
As of acquisition by Coloplast in November 2020, the product was not yet approved or commercialized. Regulatory approvals targeted for US/EU markets around 2024–2025[1][5].
No published pivotal results as of latest available data.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nine Continents Medical.